Candidate prophylactic vaccines based on papillomavirus L1 virus-like particles (VLPs) are
currently in human clinical trials. The main long-term goal of the vaccine is to reduce the …

End of study analyses of the phase III trials of prophylactic human papillomavirus (HPV)
virus-like particle (VLP) vaccines in young women are now largely completed. Two distinct …

Cervical cancer is the second largest cause of cancer-related death in women worldwide,
and it occurs following persistent infection, sometimes for decades, with a specific subset of …

Human papilloma virus (HPV) infections, which are common, produce epithelial lesions of
the nongenital and genital skin and mucous membranes. Although most infections are …

It has been estimated that genital human papillomavirus (HPV) is the most common sexually
transmitted infection in the US. Nononcogenic types, such as HPV type 6 (HPV‐6) and HPV …

'High-risk'genotypes of the human papillomavirus (HPV), most commonly HPV genotype 16,
are the primary etiologic agents of cervical cancer. Indeed HPV DNA is detected in 99% of …

It has been clearly established that sexually transmitted human papillomavirus (HPV)
infections are the major cause of genital warts and cervical cancer and are a contributing …

Routine vaccination programs have had a substantial impact on reducing the prevalence of
a variety of infectious diseases. In light of the fact that human papillomavirus (HPV) is a …

The currently licensed human papillomavirus (HPV) vaccines are safe and highly effective at
preventing HPV infection for a select number of papillomavirus types, thus decreasing the …

Genital human papillomavirus (HPV) infection and HPV‐associated cervical and other
anogenital cancers are significant public health problems. HPV 16 and HPV 18 are …